• Je něco špatně v tomto záznamu ?

Neutral sphingomyelinase 2 inhibitors based on the pyrazolo[1,5-a]pyrimidin-3-amine scaffold

K. Novotna, AG. Thomas, O. Stepanek, B. Murphy, N. Hin, J. Skacel, L. Mueller, L. Tenora, A. Pal, J. Alt, Y. Wu, J. Paule, R. Rais, BS. Slusher, T. Tsukamoto

. 2023 ; 259 (-) : 115674. [pub] 20230726

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016052

Grantová podpora
P30 MH075673 NIMH NIH HHS - United States
R01 AG059799 NIA NIH HHS - United States
T32 AG058527 NIA NIH HHS - United States

Neutral sphingomyelinase 2 (nSMase2) has gained increasing attention as a therapeutic target to regulate ceramide production in various disease conditions. Phenyl (R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)-pyrrolidin-3-yl)carbamate (PDDC) is a submicromolar nSMase2 inhibitor and has been widely used to study the pharmacological effects of nSMase2 inhibition. Through screening of compounds containing a bicyclic 5-6 fused ring, larotrectinib containing a pyrazolo[1,5-a]pyrimidine ring was identified as a low micromolar inhibitor of nSMase2. This prompted us to investigate the pyrazolo[1,5-a]pyrimidin-3-amine ring as a novel scaffold to replace the imidazo[1,2-b]pyridazine-8-amine ring of PDDC. A series of molecules containing a pyrazolo[1,5-a]pyrimidin-3-amine ring were synthesized and tested for their ability to inhibit human nSMase2. Several compounds exhibited nSMase2 inhibitory potency superior to that of PDDC. Among these, N,N-dimethyl-5-morpholinopyrazolo[1,5-a]pyrimidin-3-amine (11j) was found to be metabolically stable in liver microsomes and orally available with a favorable brain-to-plasma ratio, demonstrating the potential of pyrazolo[1,5-a]pyrimidine ring as an effective scaffold for nSMase2 inhibition.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016052
003      
CZ-PrNML
005      
20231026110524.0
007      
ta
008      
231013s2023 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2023.115674 $2 doi
035    __
$a (PubMed)37536209
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Novotna, Katerina $u Johns Hopkins Drug Discovery, United States; Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic V.v.i., Prague, 166 00, Czech Republic; Department of Organic Chemistry, Charles University, Prague, 128 00, Czech Republic
245    10
$a Neutral sphingomyelinase 2 inhibitors based on the pyrazolo[1,5-a]pyrimidin-3-amine scaffold / $c K. Novotna, AG. Thomas, O. Stepanek, B. Murphy, N. Hin, J. Skacel, L. Mueller, L. Tenora, A. Pal, J. Alt, Y. Wu, J. Paule, R. Rais, BS. Slusher, T. Tsukamoto
520    9_
$a Neutral sphingomyelinase 2 (nSMase2) has gained increasing attention as a therapeutic target to regulate ceramide production in various disease conditions. Phenyl (R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)-pyrrolidin-3-yl)carbamate (PDDC) is a submicromolar nSMase2 inhibitor and has been widely used to study the pharmacological effects of nSMase2 inhibition. Through screening of compounds containing a bicyclic 5-6 fused ring, larotrectinib containing a pyrazolo[1,5-a]pyrimidine ring was identified as a low micromolar inhibitor of nSMase2. This prompted us to investigate the pyrazolo[1,5-a]pyrimidin-3-amine ring as a novel scaffold to replace the imidazo[1,2-b]pyridazine-8-amine ring of PDDC. A series of molecules containing a pyrazolo[1,5-a]pyrimidin-3-amine ring were synthesized and tested for their ability to inhibit human nSMase2. Several compounds exhibited nSMase2 inhibitory potency superior to that of PDDC. Among these, N,N-dimethyl-5-morpholinopyrazolo[1,5-a]pyrimidin-3-amine (11j) was found to be metabolically stable in liver microsomes and orally available with a favorable brain-to-plasma ratio, demonstrating the potential of pyrazolo[1,5-a]pyrimidine ring as an effective scaffold for nSMase2 inhibition.
650    _2
$a lidé $7 D006801
650    12
$a sfingomyelinfosfodiesterasa $7 D013108
650    12
$a aminy $7 D000588
650    _2
$a pyrimidiny $x farmakologie $7 D011743
650    _2
$a ceramidy $7 D002518
655    _2
$a časopisecké články $7 D016428
700    1_
$a Thomas, Ajit G $u Johns Hopkins Drug Discovery, United States
700    1_
$a Stepanek, Ondrej $u Johns Hopkins Drug Discovery, United States; Department of Neurology, United States
700    1_
$a Murphy, Brennan $u Johns Hopkins Drug Discovery, United States; Department of Neurology, United States
700    1_
$a Hin, Niyada $u Johns Hopkins Drug Discovery, United States
700    1_
$a Skacel, Jan $u Johns Hopkins Drug Discovery, United States
700    1_
$a Mueller, Louis $u Johns Hopkins Drug Discovery, United States; Department of Neurology, United States
700    1_
$a Tenora, Lukas $u Johns Hopkins Drug Discovery, United States; Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic V.v.i., Prague, 166 00, Czech Republic
700    1_
$a Pal, Arindom $u Johns Hopkins Drug Discovery, United States; Department of Neurology, United States
700    1_
$a Alt, Jesse $u Johns Hopkins Drug Discovery, United States
700    1_
$a Wu, Ying $u Johns Hopkins Drug Discovery, United States
700    1_
$a Paule, James $u Johns Hopkins Drug Discovery, United States
700    1_
$a Rais, Rana $u Johns Hopkins Drug Discovery, United States; Department of Neurology, United States; Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, 21205, United States
700    1_
$a Slusher, Barbara S $u Johns Hopkins Drug Discovery, United States; Department of Neurology, United States; Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, 21205, United States
700    1_
$a Tsukamoto, Takashi $u Johns Hopkins Drug Discovery, United States; Department of Neurology, United States; Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, 21205, United States. Electronic address: ttsukamoto@jhmi.edu
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 259, č. - (2023), s. 115674
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37536209 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026110517 $b ABA008
999    __
$a ok $b bmc $g 1999905 $s 1202414
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 259 $c - $d 115674 $e 20230726 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
GRA    __
$a P30 MH075673 $p NIMH NIH HHS $2 United States
GRA    __
$a R01 AG059799 $p NIA NIH HHS $2 United States
GRA    __
$a T32 AG058527 $p NIA NIH HHS $2 United States
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace